

Silver in Drinking-water

Background document for development of
WHO Guidelines for Drinking-water Quality

22 December 2020

Version for public review

© World Health Organization 20XX

Preface

To be completed by WHO Secretariat

Acknowledgements

To be completed by WHO Secretariat

Abbreviations used in the text

AgNPs	Silver nanoparticles
ANSES	Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (French agency for food, environmental and occupational health & safety)
ATSDR	Agency for Toxic Substances and Disease Registry (USA)
bw	body weight
CAS	Chemical Abstracts Service
DNA	deoxyribonucleic acid
FDA	Food and drug administration (USA)
IARC	International Agency for Research on Cancer
i. p.	intra peritoneal
LD ₅₀	median lethal dose
LOAEL	lowest-observed-effect-level
NAS	National Academy of Science
NOAEL	no-observed-adverse-effect-level
NTP	National Toxicology Program (USA)
PND	Postnatal day
POD	Point of departure
PVP	Polyvinylpyrrolidone
ROS	Reactive oxygen species
SD	Sprague Dawley
spICPMS	single particle inductively coupled plasma mass spectrometry
TEM	Transmission electron microscopy
USA	United States of America
USEPA	United States Environment Protection Agency

Table of contents

1.	EXECUTIVE SUMMARY	1
2.	GENERAL DESCRIPTION	1
2.1	Identity	1
2.2	Physicochemical properties	1
2.3	Organoleptic properties	1
2.4	Major uses and sources	1
3.	ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE	2
3.1	Water	2
3.2	Food.....	2
3.3	Air.....	2
3.4	Estimated total exposure and relative contribution of drinking-water.....	3
4.	TOXICOKINETICS AND METABOLISM IN ANIMALS AND HUMANS.....	3
4.1	Absorption.....	3
4.2	Distribution.....	3
4.3	Metabolism.....	4
4.4	Elimination.....	4
5.	EFFECTS ON HUMANS.....	5
5.1	Acute exposure.....	5
5.2	Short-term exposure	5
5.3	Long-term exposure	5
5.4	Neurological effects	6
5.5	Reproductive and developmental effects	6
5.6	Immunological effects.....	6
5.7	Genotoxicity and carcinogenicity.....	6
6.	EFFECTS ON EXPERIMENTAL ANIMALS AND IN VITRO TEST SYSTEMS.....	7
6.1	Acute exposure.....	7
6.2	Short-term and subchronic exposure.....	7
6.3	Long-term exposure	7
6.4	Neurological effects	8
6.5	Reproductive and developmental effects	8
6.6	Immunological effects.....	9
6.7	Genotoxicity and carcinogenicity.....	9
6.8	In vitro systems	10
6.9	Mode of action	10
7.	OVERALL DATABASE AND QUALITY OF EVIDENCE.....	11
7.1	Summary of Health Effects	11
7.2	Quality of Evidence.....	11
8.	PRACTICAL CONSIDERATIONS.....	11
8.1	Monitoring.....	11
8.2	Analytical methods.....	11
8.3	Treatment methods and performance.....	12
8.4	Efficacy as a disinfectant.....	12
9.	CONCLUSION.....	12
9.1	Derivation of the health-based value and/or final guideline value.....	13
10.	REFERENCES	13

1 EXECUTIVE SUMMARY

2 *To be written after public review*

3 2 GENERAL DESCRIPTION

4 2.1 Identity

5 Silver (Chemical Abstracts Service [CAS] no. 7440-22-4) is a transition metal that is present in silver
6 compounds. Silver ions primarily occur in the +1 oxidation state. The silver compounds that are most
7 relevant to drinking-water are silver nitrate (AgNO₃, CAS no. 7761-88-8) and silver chloride (AgCl,
8 CAS no. 7783-90-6).
9
10

11 2.2 Physicochemical properties

12 The silver, silver nitrate, silver chloride, silver(I)oxide (Ag₂O) and silver acetate (Ag(C₂H₃O₂))
13 are summarized in Table 1.
14

15 Table 1. Physicochemical properties of silver and silver compounds

Property	Ag	AgNO ₃	AgCl	Ag ₂ O	Ag(C ₂ H ₃ O ₂)
Colour	Silver-white	White	White, darkens when exposed to light	Brown-black	White
Melting point (°C)	962	212	455	230	Not reported
Water solubility at 20 or 25 °C (g/L)	Insoluble	2 150	0.001 86	0.025	10

16 *Sources:* Holleman & Wiberg (2017), ChemID

17
18 Silver can also occur as nanoparticles (AgNP) of between 1 nm and 100 nm in size. While frequently
19 described as being 'silver' some are composed of a large percentage of Ag₂O due to their large ratio of
20 surface-to-bulk silver atoms. In addition, AgNPs can possess different coatings like bovine serum
21 albumin, tubulin or ubiquitin (Durán et al., 2015). According to the literature, the coating or corona as
22 it is also called, interacts with the cells and not the bare AgNP itself (Durán et al., 2015). Due to their
23 surface energy nanoparticles tend to be aggregated and form larger particles with reduced surface
24 energy (Shrestha et al., 2020).
25

26 2.3 Organoleptic properties

27 Silver ions and AgNP have no impact on taste, colour or odour at concentrations (maximum of
28 100 µg/L) used in drinking water treatment systems (Butkus et al., 2004; Heidarpour et al., 2011).
29 However, colloidal silver chloride concentrations above 150 µg/L cause opalescence in water (NAS,
30 1982).
31

32 2.4 Major uses and sources

33 Silver has the highest electrical and thermal conductivity of all metals (Hammond, 1994). It is used in
34 alloys with copper, mercury and other metals. Since the onset of digital photography, the importance of
35 silver salts in photography has declined substantially. Nevertheless, silver and its salts, oxides and
36 halides are still part of our daily lives, as they are used in alkaline batteries, electrical equipment, hard
37 alloys, mirrors, chemical catalysts, coins, table silver and jewelery. Silver has antibacterial
38 bacteriostatic or possibly bactericidal properties against gram negative and gram-positive bacteria alike
39 (Marin et al., 2015; WHO, 2018). Consumer products such as clothing with AgNP as an antimicrobial
40 agent have become more popular in recent years (Carlson et al., 2008).

41
42 Because of its bacteriostatic and/or bactericidal properties, silver is used in domestic water filters to
43 possibly reduce biofilm growth within the filter, or with some claims, as an additional level of
44 antimicrobial treatment (Barillo & Marx, 2014). More than 100 consumer products coated with metallic
45 silver and intended for water treatment are commercially available (De Gusseme et al., 2010). AgNP
46 are currently being tested in some experimental point-of-use treatment systems and are contained in
47 consumer products such as ceramic filters. Another popular filter system, comprised of cartridges with
48 silver-spiked activated carbon for use in table-top filters, releases silver into the drinking-water at
49 concentrations less than 25 to 50 µg/L (Garbos & Swiecicka, 2013; WHO, 2018). These applications
50 are evaluated in section 7.4.
51

52 **3 ENVIRONMENTAL LEVELS AND HUMAN EXPOSURE**

53 **3.1 Water**

54 In surface water and groundwater, silver concentrations are usually below 2 µg/L (ATSDR, 1990).
55 Average silver concentrations in these natural waters have been reported at 0.2–0.3 µg/L (USEPA,
56 1980). In the 1988 US National Inorganics and Radionuclides Survey, 982 of 989 (99.3%) randomly
57 selected groundwaters had concentrations less than 4 µg/L and 4 of 989 (0.4%) had concentrations
58 between 18 and 20 µg/L. In river water, silver ions form complexes with chloride and humic matter
59 (Whitlow & Rice, 1985). AgNP can be mobile and enter ground and drinking-water supplies when
60 released to the environment via wastewater or industrial discharges. The final thermodynamic sink for
61 AgNPs is believed to be insoluble AgS (Schaumann et al., 2014).
62

63 Silver concentrations in drinking-water in the USA that were not treated with silver for disinfection
64 purposes varied between “non-detectable” and 5 µg/L (USEPA, 1980). In a survey of Canadian tap
65 water, only 0.1% of the samples contained Silver at concentrations above 1–5 µg/L (Neri et al., 1974).
66

67 A more recent report on “Naturally Occurring Groundwater Contamination in Texas” prepared for the
68 Texas Water Development Board detected silver in 73 of 5420 groundwater samples (1.3%) with only
69 one detection (112 µg/L) exceeding the USEPA secondary (aesthetics-based) standard of 100 µg/L
70 (Reedy et al., 2011). Maximum values in the other aquifers ranged from not detected to 67 µg/L with a
71 median value of 1.1 µg/L. The French agency for food, environmental and occupational health & safety
72 (ANSES) estimated the mean silver concentration in drinking-water to be between 8 and 49 µg/L
73 (ANSES, 2011).
74

75 **3.2 Food**

76 It has been known for decades that food contains trace amounts of silver (Kent & McCance, 1941;
77 Murthy & Rhea, 1968). The Second French Total Diet Study found the highest concentrations of silver
78 in crustaceans and offal, with mean concentrations of 6.48 mg/kg and 0.45 mg/kg, respectively
79 (ANSES, 2011). In most other food, the silver concentration was below 0.1 mg/kg. The results of this
80 total diet study are, largely, in accordance with a study by Gibson & Scythes (1984), who found that
81 most foods contain traces of silver in the 10–100 µg/kg range.
82

83 **3.3 Air**

84 According to the Agency for Toxic Substances and Disease Registry of the United States of America
85 (USA), naturally occurring concentrations of silver in ambient air are in the nanogram per cubic metre
86 range (ATSDR, 1990).
87

88 Occupational exposure is the primary source for the inhalation of silver dusts or fumes by humans
89 (Drake & Hazelwood, 2005). In comparison to the inhalation of silver as aerosols in occupational

90 settings, the amount of silver possibly inhaled during bathing or showering would be negligible.

91

92 **3.4 Estimated total exposure and relative contribution of drinking-water**

93 Most silver and its salts are naturally-occurring, and the trace element content of food is influenced by
94 geographic origin, soil type, fertilizers and processing methods (Gibson & Scythes, 1984). In France,
95 the mean dietary exposure to silver was estimated to be between 1.29 and 2.65 µg/kg bw in adults and
96 between 1.60 and 3.47 µg/kg bw in children (ANSES, 2011). For an adult with a body weight of 60 kg,
97 this would result in an overall exposure from food of between 77 and 160 µg/person per day. Estimates
98 of daily intake of silver vary widely from about 0.4 µg/person in Italy and 10–44 µg/person in the
99 United Kingdom (Warrington, 1996). The disparity in these exposure estimates may be related to
100 differences in exposure assessment methods as well as the intake sources considered.

101

102 The contribution of drinking-water to overall silver exposure varies considerably. In Canada, it is
103 estimated that about 1% of silver exposure is from drinking-water (Warrington, 1996), whereas
104 estimates from France range from 8% to 20% (ANSES, 2011). Where silver salts are used as
105 bacteriostatic agents in water treatment (up to 100 µg/L), the daily intake of silver from drinking-water
106 probably constitutes the major source of exposure.

107

108 **4 TOXICOKINETICS AND METABOLISM IN ANIMALS AND HUMANS**

109

110 Silver can be found either in its ionic or (nano)particulate form. In addition, AgNP also release silver
111 ions (Kittler et al., 2011). It is therefore difficult to distinguish whether an effect seen after exposure to
112 AgNP is caused by the particles or the ions released.

113

114 **4.1 Absorption**

115 Silver can be absorbed via the gastrointestinal tract, lungs, mucous membranes and skin lesions
116 (Loeschner et al., 2011; Munger et al., 2014; Pelkonen et al., 2003; USEPA, 1980; van der Zande et al.,
117 2012). The absorption of colloidal silver after oral exposures can be as high as 5% (USEPA, 1980). The
118 absorption from the GI tract of ionic silver, as AgNO₃ or silver acetate, is higher than that from AgNPs
119 (Loeschner et al., 2011; Van der Zande et al., 2012). Data on fecal elimination in rats exposed to
120 approximately 9 mg/kg-day AgAc or polyvinylpyrrolidone coated AgNP (Loeschner et al., 2011)
121 suggests that silver acetate has a higher bioavailability than AgNP, as 63% of the administered dose of
122 AgNP was eliminated in the faeces over a 24-hour period vs. only 49% of the administered dose of
123 silver acetate. Another study in rats showed that the bioavailability of colloidal AgNP in a protein matrix
124 from water is between 1 and 4 % when animals were treated with 1 and 10 mg/kg bw, respectively
125 (Park et al., 2011). Water hardness may reduce the bioavailability of AgNPs by increasing their
126 aggregation and by competition with the physiological transport mechanism, an effect that may vary
127 with the particle coating (Stoiber et al., 2015). A case study by East et al. (1980) reported a silver
128 retention rate of 18% after oral ingestion of lozenges containing silver acetate as an anti-smoking
129 remedy.

130

131 **4.2 Distribution**

132 Most of the silver ion transported in blood is bound to globulins (USEPA, 1980). In tissues, it is present
133 in the cytosolic fraction, bound to metallothionein (Nordberg & Gerhardsson, 1988). Silver is stored
134 mainly in liver and skin with smaller amounts in other organs (Furchner, Richmond & Drake, 1968;
135 USEPA, 1980). Silver is also deposited in the skin epidermis, renal glomeruli and intestine in nanosized
136 particles, regardless of whether exposure occurred as ions or AgNP (Hadrup & Lam, 2014).

137

138 Silver crosses the blood–brain barrier in rats after exposure in drinking-water (Pelkonen & Hanninen

139 2003; Van der Zande et al. 2012). Deposition of AgNPs of different sizes (22, 42 and 71 nm) was
140 observed in brain, lung, liver, kidney and testis after 14 days of oral administration of 1 mg/kg bw per
141 day in mice (Park et al., 2010). Larger particles (323 nm) were not found in those tissues.

142
143 Studies on the ability of AgNPs to cross the blood-placenta boundary give equivocal results. Ema et al.
144 (2017) reviewed studies that found AgNPs in foetal tissues of mice and rats treated with 0.2 to 1000
145 mg/kg bw. Other studies using orally applicated AgNPs with a size of 8.8 nm did not induce
146 reproductive, developmental, or repeated dose toxicity at 62.5–250 mg/kg/day. (Ema et al., 2017).
147 Reasons for those conflicting results might relate to the different time points of application during
148 pregnancy, different intervals between application and necropsy or size differences of the AgNP used.

149
150 Silver was identified in human brain tissues at concentrations of up to 5 µg/kg wet weight (Drasch et
151 al., 1995) with the level of silver in brain tissue shown to be correlated with the number of dental
152 amalgam fillings in human subjects (Drasch et al., 1995; Skare & Enqvist, 1994). Lyon et al. (2002)
153 attributed the origin of significant amounts of silver in the livers of children 6 years of age or younger
154 to maternal dental amalgams because of exposures during pregnancy and lactation.

155
156 A US FDA study evaluated tissue accumulation and distribution of silver in SD rats exposed by oral
157 gavage to AgNP or ionic silver for 13 weeks (Boudreau et al., 2016). Treatment groups included those
158 receiving citrate-coated AgNP (10, 75, or 110 nm) at 9, 18, or 36 mg/kg bw per day; silver acetate
159 (AgAc) at 100, 200, or 400 mg/kg bw per day; and controls (2 mM sodium citrate or water). Significant
160 dose-dependent and AgNP size-dependent accumulations were detected in tissues. Sex differences in
161 silver accumulations were noted for many tissues and organs, with accumulations being significantly
162 higher in female rats, especially in the kidney, liver, jejunum, and colon.

163
164 After gavage of AgNP (70 nm diameter) in rats at 1 and 2 mg/kg bw per day for 30 days, damages were
165 seen in the tissues of liver, kidneys and spleen (Sardari et al., 2012). Since no AgNP were seen in these
166 tissues, the authors concluded that silver ions were interfering with the intercellular redox balance.

167
168 In mice exposed to 0.03 mg/L as silver nitrate in drinking water for 1 or 2 weeks, silver was found in
169 brain, muscle, spleen and other tissues at concentrations between 1 and 29 µg/kg wet weight (Pelkonen
170 et al., 2003). The dose was adjusted for silver ion concentration (5.7 µg/kg bw/day) with an assumption
171 of a 0.03 kg bw and 0.0057 L/day intake. The 0.03 mg/L concentration used in this study is well below
172 the maximum concentration of 0.1 mg/L silver allowed in many countries.

173
174 Rats were exposed to ionic silver at 9 mg/kw bw per day or AgNP at 90 mg/kg bw per day (PVP-coated
175 or uncoated with a diameter of 15 or 20 nm, respectively) for 28 days via gavage (Van der Zande et al.,
176 2012). Samples of liver, spleen, testis, kidney, brain, lungs, blood, bladder and heart, plus the wall of
177 stomach, small and large intestine were evaluated for ionic silver and AgNP content either on day 29
178 or after a wash out period of 1 or 8 weeks. When these large doses were adjusted for concentration, the
179 total amount of ionic silver found in different tissues was always higher than the amount of AgNPs.
180 After 8 weeks, brain and testis were the only organs from which silver was not washed out.

181

182 **4.3 *Metabolism***

183 After uptake, metallic silver is converted into its ionic form by moisture and body fluids such as saliva
184 and stomach fluid. Silver ions are biologically active and bind to sulphhydryl groups and other anionic
185 ligands present in proteins and other cell constituents such as glutathione and cysteine (Hadrup & Lam,
186 2014).

187

188 **4.4 *Elimination***

189 The liver plays a key role in silver excretion; most absorbed silver is excreted with the bile in the faeces.
190 The biological half-life of silver in humans (liver) ranges from several to 50 days (Nordberg &
191 Gerhardsson, 1988). Silver that is not eliminated is ultimately oxidized to silver sulphide. This
192 compound is responsible for the grey-bluish discoloration of the skin of humans, referred to as argyria
193 (Drake & Hazelwood, 2005). In mice, rats, monkeys and dogs, cumulative silver excretion was in the
194 range 90–99% of the intake. Silver retention was about 10% in the dog, <5% in the monkey and <1%
195 in rodents (Furchner et al., 1968). In humans, under conditions where silver exposure occurs daily,
196 retention rates between 0% and 10% have been observed (USEPA, 1980).

197
198 Two studies performed by Loeschner et al. (2011) and Van der Zande et al. (2012) showed that most
199 silver (between 50 and 99 %) is eliminated via the faeces, both for ionic silver and AgNP. Since a higher
200 percentage of AgNP are found in the faeces compared to ionic silver, their bioavailability seems to be
201 lower.

202
203 Both ionic silver and AgNPs are cleared from the blood stream in less than one week (Van der Zande
204 et al., 2012).

205

206 **5 EFFECTS ON HUMANS**

207 **5.1 Acute exposure**

208 The estimated acute lethal dose of silver nitrate in humans is at least 10 g (Hill & Pillsbury, 1939). More
209 recent data were not identified.

210

211 Irritation of the upper and lower respiratory tract observed after inhalation of silver nitrate is probably
212 attributable to nitrate rather than the silver itself (Drake & Hazelwood, 2005). There is one case report
213 of severe but reversible respiratory problems due to occupational exposure associated with processing
214 of molten silver (ATSDR, 1990).

215

216 **5.2 Short-term exposure**

217 In a study by Munger et al. (2014), 60 healthy subjects of both sexes aged 18 – 80 years were treated
218 with one single daily dose of elemental AgNP coated with silver oxide for 3, 7 or 14 days. The
219 hydrodynamic diameter of the particle was 59.8 ± 20 nm. The applied dose was either 2.5 µg/kg bw or
220 7.9 µg/kg bw based on a 60 kg adult. No clinically relevant changes in body weight, blood pressure,
221 metabolic markers or cellular composition of blood were observed in any group.

222 **5.3 Long-term exposure**

223 The only known clinical picture of chronic silver intoxication is that for argyria, a condition where
224 silver is deposited on skin and hair and in various organs following occupational or iatrogenic exposure
225 to metallic silver and its compounds. Pigmentation of the eye is considered the first sign of generalized
226 argyria (Hill & Pillsbury, 1939). Striking discoloration, which occurs particularly in areas of the skin
227 exposed to light, is attributed to the photochemical reduction of silver in the accumulated silver
228 compounds, mainly silver sulphide. Melanin production has also been stimulated in some cases (East
229 et al., 1980; Westhofen & Schäfer, 1986). As there is no effective treatment for argyria, the effect is
230 permanent, even if the uptake of silver is discontinued (Drake & Hazelwood, 2005).

231

232 It is difficult to determine the lowest dose that may lead to the development of argyria. A patient who
233 developed grey pigmentation on the face and neck after taking an unknown number of anti-smoking
234 pills containing silver ethanoate had a total body silver content of 6.4 ± 2 g (East et al., 1980). Localized
235 argyria (i.e. discoloration of the nail bed) was found in a patient who ingested 1.5 g of silver, and
236 generalized argyria can be induced by total amounts of silver as low as 3 g (Kim et al., 2009).
237 Intravenous administration of 4.1 g of silver arsenamine (about 0.6 g of silver) can lead to argyria

238 (Gaul & Staud, 1935). Other investigators concluded that the lowest intravenous dose of silver
239 arsphenamine causing argyria in syphilis patients was 6.3 g (about 0.9 g of silver) (Hill & Pillsbury,
240 1939). It should be noted that syphilis patients suffering from argyria were already in a compromised
241 state of health and were treated with bismuth, mercury or arsphenamine in addition to silver.
242

243 Kim et al. (2009) presented a case report of a woman, with diffuse blue-gray discoloration of the skin,
244 who ingested about 34 mg colloidal silver per day for approximately 16 months (0.6 mg/kg assuming
245 60 kg bw). Her serum copper level was about one third of the lower normal range, her ceruloplasmin
246 level about 50% of the lower normal range suggesting that silver may alter copper metabolism by
247 decreasing serum copper concentrations and ceruloplasmin oxidase activity.
248

249 Inhalation exposure to silver is usually occupational. Workers exposed to silver nitrate and/or silver
250 oxide at concentrations of 0.039 to 0.378 mg silver/m³ for less than one to more than 10 years developed
251 irritation of the upper and lower respiratory tract and occasional gastric discomfort without effects on
252 the cardiovascular system or blood counts (ATSDR, 1990).
253

254 **5.4 *Neurological effects***

255 The literature research did not identify any studies on potential neurotoxic effects of silver in
256 humans.
257

258 **5.5 *Reproductive and developmental effects***

259 The literature research did not identify any studies on potential reproductive or developmental
260 effects of silver in humans.

261 **5.6 *Immunological effects***

262 Hypersensitivity to silver-containing compounds was reported in individuals previously sensitized by
263 working as silver miners, jewellers or photographers (Sterling, 2014). Hypersensitivity to silver
264 sulfadiazine was reported however, it is not clear whether the hypersensitivity was caused by silver or
265 sulfadiazine (Sterling, 2014).
266

267 **5.7 *Genotoxicity and carcinogenicity***

268 The United States Environmental Protection Agency states that “No evidence of cancer in humans has
269 been reported despite frequent therapeutic use of the compound over the years” (USEPA, 2014). No
270 monograph on silver is available from the International Agency for Research on Cancer (IARC, 2018).
271 In addition, silver is not listed in NTP’s 14th Report on Carcinogens (NTP, 2016).
272

273 Significantly increased DNA damage in peripheral leucocytes was reported in Turkish jewelry workers
274 exposed to airborne silver particles of unspecified size for at least four hours per day for an unknown
275 duration (Aktepe et al., 2015). The authors proposed that direct interaction of (nano-)particles with
276 DNA and excessive reactive oxygen species (ROS) were responsible for the damage; however, no data
277 or further details were included. Due to the limited number of participants (35 and 41 for exposure and
278 control groups, respectively), confounding factors such as cigarette smoking, co-exposure to other
279 genotoxic metals, and unknown exposure concentrations, the reported results should be interpreted with
280 caution (WHO, 2018).
281

282 Epidemiological studies investigating other health effects including the carcinogenicity of silver were
283 not identified.
284

285 6 EFFECTS ON EXPERIMENTAL ANIMALS AND IN VITRO TEST SYSTEMS¹**286 6.1 Acute exposure**

287 Median lethal doses (LD₅₀ values) of 50 mg/kg bw for AgNO₃ and silver dinaphthylmethane
288 disulphonate and 100 mg/kg bw for colloidal silver were determined in mice (Goldberg et al., 1950). A
289 more recent study by Maneewattanapinyo et al. (2011) found no acute effects in mice after oral
290 administration of 5,000 mg/kg bw colloidal AgNP. One reason for the different LD₅₀ values might be
291 the higher bioavailability of ionic silver compared to AgNP as shown in the paper by Van der Zande et
292 al. (2012).

294 6.2 Short-term and subchronic exposure

295 Death was observed in rats following ingestion of 1680 mg/kg bw colloidal silver after oral dosing for
296 4 days (Dequidt et al., 1974). A drinking-water concentration of 2.6 g/L (364 mg/kg assuming 0.35 kg
297 bw and 0.049 L water intake) silver was reported to be fatal for rats (Warrington, 1996); however, no
298 further details regarding the chemical form(s) of silver were available.

300 Rats receiving silver nitrate daily for 2 weeks in their drinking-water survived at 181 mg/kg bw per day,
301 but 3 of 12 died at 362 mg/kg bw per day (Walker, 1971).

303 Ten SD rats per sex and dose received AgNP (52.7-70.9 nm, average 60 nm; ≥99.98% purity in 0.5%
304 carboxymethylcellulose (unspecified whether coated or not) via gavage at 0, 30, 300, or 1,000 mg/kg-
305 day for 28 days (Kim et al., 2008). At 300 mg/kg-day, mean absolute liver weight was increased
306 (p<0.05) in female rats by an unspecified magnitude. At 1,000 mg/kg-day, mean absolute brain weight
307 was increased (p<0.05) in male rats by an unspecified magnitude. The study authors also reported
308 increased incidence of bile duct hyperplasia in AgNP-exposed rats, but the dose level(s) associated with
309 this effect were not specified.

311 6.3 Long-term exposure

312 No standardized chronic studies for silver or AgNP were identified. Increased pigmentation of different
313 organs, including the eye, was observed in Osborne-Mendel rats after a lifetime exposure to silver at
314 approximately 60 mg/kg bw per day as silver nitrate or silver chloride from their drinking-water (Olcott,
315 1947). After 218 days of exposure (~31 weeks), albino rats receiving a silver dose of approximately 60
316 mg/kg bw per day from their drinking-water containing either silver nitrate or silver chloride as salts
317 exhibited a slight greyish pigmentation of the eyes, which later intensified (Olcott, 1950).

319 In a 90-day gavage study, F344 rats were exposed to 0, 30, 125 or 500 mg/kg bw AgNPs with a median
320 diameter of 56 nm (Kim et al., 2010). Increased incidence of bile duct hyperplasia of minimal severity
321 as well as increased incidence of liver necrosis of minimal severity were observed in both sexes at all
322 doses; no other histopathological effects deemed adverse by the study authors were reported. A dose-
323 dependent increase in silver deposition was observed in the brain, liver, kidneys, lungs and blood, with
324 a higher deposition in the kidneys of female rats. Based on the results of the study, the authors proposed
325 a NOAEL and LOAEL of 30 and 125 mg/kg-day respectively, likely based on significantly reduced
326 mean body weights and significantly increased mean serum cholesterol and bilirubin levels in the mid-
327 and high-dose groups.

328
329 An OECD 408-compliant US FDA study evaluated nano-particulate and ionic forms of silver and

¹ Additional information on the effects of silver nanoparticles and ionic silver in experimental animals and humans may be found in WHO (2018); the information provided here on AgNP and ionic silver has been summarized from that report with the inclusion of additional studies.

330 particle size for differences in silver accumulation, distribution, morphology, and toxicity after daily
331 oral gavage to 10 SD rats per sex and dose for 13 weeks (Boudreau et al., 2016). Treatment groups
332 included citrate-coated AgNP (10, 75, and 110 nm) at 9, 18, or 36 mg/kg bw per day; silver acetate
333 (AgAc) at 100, 200, or 400 mg/kg bw per day; and controls (2 mM sodium citrate or water). Terminal
334 necropsy, histopathology, hematology, and serum chemistry were performed. Rats exposed to AgNP
335 did not show significant changes in body weights or intakes of feed and water relative to controls. Blood
336 levels were similar to controls. Histopathology of the following organs was performed after exposing
337 the animals to AgNP (36 mg/kg bw/day) or AgAc (64.6 mg silver/kg bw/day): jejunum, ileum, colon,
338 kidney, liver, and spleen. The authors considered the pigmentation to be more a measure of silver
339 mobility rather than toxicity, because the pigmentation did not induce lesions that were visible by light
340 microscopy. Therefore, Boudreau et al. did not identify a NOAEL for AgAc. However, it is recognized
341 that argyria in humans is permanent even after exposure is discontinued because no treatment is
342 available. Thus, the lowest dose tested of AgAc (100 mg/kg) could be classified as a LOAEL for argyria.
343 For AgNP, 18 mg/kg/day is the NOAEL for pigment deposition with 36 mg/kg bw per day as the
344 LOAEL, recognizing that no histopathological lesions were seen at this dose.

345
346 If the pigmentation is considered as nonadverse the dose of 200 mg/kg bw per day would be the NOAEL
347 for AgAc while 400 mg/kg/day would be the LOAEL for AgAc based on the increased incidence and
348 severities of histopathological lesions at the highest dose. Histopathological lesions included mucosal
349 hyperplasia in the small and large intestine and thymic atrophy or necrosis. The authors considered the
350 thymic response to be stress-related because of the observed gastrointestinal disturbances.

351
352 Weanling rats treated with drinking-water containing 1.6 g/L of silver given as silver nitrate for 37
353 weeks showed reduced weight gain compared with rats treated with the same water for 10 weeks and
354 allowed 27 weeks of recovery. Some of the rats treated with silver-containing drinking-water started
355 losing weight rapidly after 23 weeks and eventually died (Matuk et al., 1981). Assuming 0.011 L/day
356 water intake and 0.05 kg bw for weanling rats, the rats received approximately 0.35 mg/kg bw per day
357

358 **6.4 Neurological effects**

359 Hypoactivity was observed in mice receiving a silver dose of 4.5 mg/kg bw per day provided as silver
360 nitrate via drinking-water at 95 mg/L silver) for 125 days (Rungby & Danscher, 1984). A more in-depth
361 review of possible neurological effects can be obtained from the WHO document “Silver as a drinking-
362 water disinfectant” (WHO, 2018).

363

364 **6.5 Reproductive and developmental effects**

365 In a developmental toxicity study, Price and George (2002) administered gavage doses of 10, 30 or
366 100 mg silver acetate/kg bw per day to pregnant female SD rats during GD 6 to 19. The test substance
367 used in the study contained approximately 65% silver by weight. In the maternal animals, the study
368 authors reported a statistically significant trend ($p < 0.05$) of reduced body weight on GD 12; however,
369 the group pairwise comparisons to the control mean were not statistically significant. The study authors
370 also reported increased frequency of rooting and piloerection in the mid- and high-dose dams. There
371 were no treatment-related developmental effects reported in the offspring. Based on the results of the
372 study, the authors identified a maternal NOAEL of 10 mg silver acetate/kg bw per day (6.5 mg silver/kg
373 bw per day) and a developmental NOAEL of 100 mg/silver acetate/kg bw per day (65 mg silver/kg bw
374 per day).

375

376 No loss of fertility was reported in either sex exposed to ionic silver in drinking-water (as silver nitrate
377 or as silver chloride) at a dose of 89 mg/kg bw per day (Olcott, 1948; as summarized by ATSDR, 1990).
378 Ionic silver was not deposited in the testes, and the spermatozoa appeared normal (Olcott, 1948).

379

380 Boudreau et al. (2016) tested ionic or AgNP for differences in sperm motility, testis sperm count, caudal
381 sperm count, or sperm morphology in exposed male SD rats and differences in the estrous cycle in
382 exposed female SD rats. Animals were 7 weeks old at the beginning of the treatment. No significant
383 effects were found in any group given either citrate-coated AgNP (10, 75, and 110 nm diameter) at 9,
384 18, or 36 mg/kg bw per day or silver acetate (AgAc) at 100, 200, or 400 mg/kg bw per day for 13 weeks
385 (Boudreau et al., 2016).

386
387 0, 15 or 50 µg/kg bw citrate-coated AgNP (60 nm diameter) were administered to male Wistar rats
388 during the prepubertal period for 30 days starting at PND 23 by oral gavage. When examined as adults,
389 impaired spermatogenesis, and reduced sperm count were observed at 15 µg/kg bw (Sleiman et al.,
390 2013). This concentration seems to be extremely low compared to other AgNP studies, but since the
391 publication provides no further information on the preparation of the suspensions or the experimental
392 procedures, a re-calculation of the concentrations and confirmation of the administered dose is not
393 possible. Also, the fact that treatments started at different points in development doesn't seem to account
394 for the disparity in the observations.

395
396 In adult male rabbits, intravenous exposure to AgNP at 0.6 mg/kg bw decreased sperm velocity and
397 mobility with AgNPs visible in the acrosome and the mitochondria of the sperm cells (Castellini et al.,
398 2014).

399
400 In a 90-day study by Thakur et al. (2014) citrate-coated AgNPs with a diameter of 5- 20 nm were
401 administered by oral gavage at 0 or 20 µg/kg bw per day to eight male rats. Structural damages observed
402 through TEM included depletion of germ cells and germinal cells necrosis. Again, this dose is extremely
403 low with no information to confirm the concentration of AgNP in the administered suspension.

404
405 The very limited available data on potential reproductive and developmental toxicity of AgNPs in
406 rabbits, mice or rats has been critically reviewed by Ema et al. (2017). The authors concluded that
407 further studies using state-of-the-art methodologies and relevant routes and doses for human exposure
408 are required to substantiate the finding of (Thakur et al (2014)).

409

410 **6.6 Immunological effects**

411 In a 28-day study, Park et al. (2010) tested for immunological effects of uncoated AgNPs with a
412 diameter of 42 nm after oral gavage in mice at 0, 0.25, 0.5 and 1 mg/kg bw per day. Deposition in liver
413 and kidney and an increase in cytokines (IL-1, IL-4, IL-6, IL-10, IL-12 and TGF-β) were observed at 1
414 mg/kg bw per day. The NOAEL can be considered 0.5 mg/kg bw per day.

415
416 Increases in oxidative stress and cellular Zn²⁺ and decreases in nitric oxide, an immune effector, were
417 reported in cultured mouse monocyte cells (RAW 264.7) exposed to polyester stabilized AgNP with 5
418 different mean sizes ranging from 2.0 to 34.7 nm or ionic silver (Haase et al., 2014). Silver concentration
419 were 10 µM in all settings. The functional relevance of the responses observed in the cultured cells is
420 unclear.

421

422 **6.7 In vivo genotoxicity and carcinogenicity**

423 In male and female SD rats, oral administration of AgNP up to 1000 mg/kg bw per day for 28
424 days (Kim et al., 2008), or up to 36 mg/kg bw per day AgNP for 90 days (Boudreau et al.,
425 2016), did not induce statistically significant increases in micronucleus formation. The reason
426 for the large disparity in the tested doses of AgNP between these two studies is unclear;
427 however, Boudreau et al. (2016) conducted stability studies and determined that the tested dose
428 was the maximum dose level that could be achieved with the sodium citrate stabilizing agent,
429 whereas Kim et al. (2008) included limited discussion of AgNP characterization and stability.

430 A small but statistically significant increase in the frequency of micronucleated reticulocytes in
431 peripheral blood sampled at week 4 was reported in both male and female rats given 400 mg/kg bw per
432 day silver acetate (Boudreau et al., 2016); however, this increase was not observed at subsequent time
433 points and is therefore of doubtful significance. Overall the weight of evidence indicates that silver is
434 not a significant genotoxic concern.

435
436 No oral carcinogenicity studies for silver were identified. Fibrosarcomas have been induced in rats
437 following subcutaneous imbedding of silver foil (Oppenheimer et al., 1956) while positive (Schmahl
438 and Steinoff, 1960) and negative (Furst & Schlauder, 1978) results for tumorigenesis was reported in
439 rats following subcutaneous and intramuscular injection, respectively of colloidal silver. Most of the
440 tumours (6/7) were found at the injection side. However, these studies represent a very different
441 exposure scenario compared to ingestion of drinking-water and such studies are not considered to be
442 relevant in assessing hazards due to systemic exposure, such as from drinking-water and so the data are
443 of very limited value.

444 **6.8 *In vitro* genotoxicity**

446 No mutagenic effects were reported in several *in vitro* bacteria reverse mutation assays after applying
447 silver chloride or silver particles of different sizes, including the nano-size range (Nishioka, 1975,
448 Asakura et al., 2009, Li et al. 2012). In an *in vitro* micronucleus study conducted in the Chinese hamster
449 ovary cell line (CHO-1K) (Jiang et al., 2013), there was a concentration-dependent increase in the
450 frequency of DNA adduct and micronucleus formation in cells treated with ionic silver and AgNP.
451 However, no mechanism for this was proposed.

452 **6.9 *Other in vitro* studies**

454 There has been a recent increase in studies scrutinizing the toxicology of silver ions and AgNP. This is
455 probably due to an ever-expanding market of applications for AgNPs. A wide variety of cells from
456 different tissues have been tested, i.e. brain, blood, bone, liver, kidney, lung, cervix and testes (WHO,
457 2018). The cells were derived from humans, rats, mice hamsters or pigs. Besides being of non-human
458 origin, many cells were secondary cells (i.e. cancer-derived or immortalised cell lines) reducing
459 relevance to human exposures even further. In primary cells, exposure to silver (ionic or AgNP) resulted
460 in oxidative stress. Silver was cytotoxic in lung macrophages and fibroblasts plus brain cells. A
461 cytotoxic effect on human blood mononuclear cells was observed at concentrations as low as 1 µg/mL
462 (WHO, 2018).

463
464 The relevance of these *in vitro* findings to exposure of humans from drinking-water is unknown and
465 questionable because cell lines have different properties compared to whole organisms. First, since cell
466 lines are directly exposed to the test compound, *in vitro* studies do not account for limited absorption
467 of the substance in the whole organism. Secondly, since silver ions bind to serum globulins and
468 metallothionein, *in vivo* exposure of cells in humans will be very different.

469 **6.10 *Mode of action***

471 Since there are limited data on silver toxicity, it is difficult to define a mode of action. As discussed by
472 Aktepe et al. (2015) the formation of ROS after inhalation of silver particles by jewellery workers is a
473 possible explanation for silver toxicity. However, the relevance of this mode of action to exposure
474 through drinking-water is unclear.

475
476 The formation of ROS was observed after exposure of cells from different tissues to silver, e.g. lung,
477 liver, kidney, blood, skin and brain, both of human and animal origin in *in vitro* systems (WHO, 2018).
478 Changes in the delicate redox balance of cells are often regarded as precursor events for cytotoxicity

479 and genotoxicity. However, translation from in vitro to in vivo exposures is difficult for the reasons
480 described in section 6.9, Hadrup and Lam (2014) also noted that silver might be deposited as nano-sized
481 granules, which results in mechanical disruption of anatomical structures. This property was described
482 for both colloidal silver and AgNP after oral uptake (Hadrup & Lam, 2014).
483

484 **7 OVERALL DATABASE AND QUALITY OF EVIDENCE**

485 **7.1 Summary of Health Effects**

486 Silver is deposited in various organs (e.g. skin, kidney, liver) after oral ingestion in its ionic form and
487 as AgNP. Silver that remains in the body is ultimately oxidized to insoluble Ag₂S, which is responsible
488 for skin darkening characteristic for humans suffering from argyria. Respiratory problems induced by
489 inhalation are not relevant for drinking-water and tend to result from occupational rather than general
490 population exposure. Lansdown (2010) reviewed the safety of silver ions used in medical applications,
491 including wound dressings and treating burns and concluded that health risks associated with systemic
492 absorption of silver as ions are low.
493

494 **7.2 Quality of Evidence**

495 The limited studies on potential neurotoxicity and carcinogenicity of silver is a clear deficiency in the
496 database, although there are no significant indications that these are likely to be an issue, particularly at
497 low intakes in view of the propensity of silver ions to bind to sulphide groups and to form insoluble
498 silver halides. Silver has been used by humans in various ways, including ways resulting in ingestion
499 since about 3000 B.C., thus it seems reasonable to assume that severe effects from exposure would be
500 historically evident (Holleman & Wiberg, 2017). However, the use of silver as nanoparticles in water
501 treatment and other applications is recent. The age of AgNP studies varies considerably, spanning a
502 time period of years not centuries while the reliability of the data from some AgNP studies is uncertain.
503

504 **8 PRACTICAL CONSIDERATIONS**

505 **8.1 Monitoring**

506 Routine monitoring of silver concentrations in drinking-water is not presently recommended. The
507 primary source of silver in drinking-water is from the use of silver in point of use water treatment
508 devices intended for disinfection purposes rather than as a disinfectant in water treatment plants. This
509 application is not recommended, because its usefulness is not proven. When detected in drinking-water,
510 the concentrations are usually in the low or sub µg/L range. When silver is added to these point of use
511 devices, they should ideally be tested and certified to not allow silver concentrations in water to exceed
512 0.1 µg/l (see section 8.1) during their useful life. See section 7.4 for more information on use of silver
513 as a drinking-water disinfectant.
514

515 Where silver/copper ions are used to control Legionella in the distribution system of buildings the
516 dosing system should be calibrated to determine the amounts of silver and copper being released.
517 Regular maintenance and occasional monitoring is necessary to ensure that the concentrations remain
518 sufficient to exert control but not excessively high, particularly if cold water drinking-water systems
519 are being treated. Frequently only the hot water side of the distribution system is treated for legionella
520 management because *-Legionella* proliferate in warmer water, so monitoring copper or silver
521 concentrations is less important in those cases, other than to ensure sufficient concentrations for
522 efficacy.
523

524 **8.2 Analytical methods**

525 The limit of detection for silver using a spectrographic and colorimetric method with dithizone is 10

526 µg/L for a 20 mL sample. The limit of detection for silver using graphite furnace atomic absorption
527 spectroscopy is 2 µg/L, and using neutron activation analysis, 2 ng/L (Fowler & Nordberg, 1986). For
528 inductively coupled plasma mass spectroscopy, the Ag detection limit is 5 ng/L (USEPA, 2007). A new
529 technique called asymmetric flow field-flow-fractionation (AF4) in combination with single particle
530 inductively coupled plasma mass spectrometry (spICPMS) can differentiate between AgNPs and
531 dissolved silver (Huynh et al., 2016). This is not yet a standard procedure (Huynh, et al., 2016). For
532 AgNPs a detection limit of 1-5 ng/L is described by Hetzer et al. for spICPMS (2017). However, ionic
533 silver can be released from AgNP (Kittler et al., 2011). Therefore, it may be difficult to determine
534 whether silver dispersed in water is originating from the ionic or the particulate fraction.
535

536 **8.3 Treatment methods and performance**

537 Ionic silver is readily removed during water treatment by conventional coagulation and lime-softening
538 techniques (USEPA, 1977). Ionic silver will precipitate and form complexes of low solubility, in the
539 presence of halides such as chloride (Sousa & Teixeira, 2015), which is common in many water
540 treatment environments. Alum and ferric sulfate coagulation achieve removal rates of approx. 80
541 percent in the pH range 6 to 8. Because of poor alum floc formation under alkaline conditions, this
542 method is less effective above pH 8. Lime softening removes from 75 to 90 percent silver in the pH
543 range 9 to 11.5 (USEPA, 1977).
544

545 A recently published paper by Salih et al. (2019) showed that conventional treatment could also be
546 sufficient for the removal of coated AgNPs.
547

548 **8.4 Efficacy as a disinfectant**

549 Silver is used in some drinking-water treatment devices in both granular and powdered activated carbon
550 filters and in domestic ceramic water filters. Although silver is widely used to reduce microbial growth
551 on filter media, its efficacy as a disinfectant is doubtful. Drawing a conclusion about the efficacy of
552 silver as a disinfectant is difficult, because researchers used many different approaches and a variety of
553 devices. The type of silver tested and doses and times varied from ionic silver to AgNP which were
554 either pure or capped with some secondary material. A comprehensive review of the literature
555 concluded that in its current applications, silver is not an effective drinking-water disinfectant (WHO,
556 2018). One reason for this conclusion is that a limited number of different microorganisms has been
557 evaluated with mixed results. It has generally been only been found to be effective against bacteria,
558 particularly *Escherichia coli* with long contact times relative to standard primary disinfectants like
559 chlorine (WHO, 2018).
560

561 In most studies, it was not clear whether silver was bactericidal or merely bacteriostatic. The evidence
562 is particularly limited for inactivation of protozoa and viruses, although some additional studies have
563 been identified since the publication of the WHO, 2018 report. These more recent studies show limited
564 inactivation of protozoa and viruses at long contact times. Thus, the overall weight of the evidence
565 indicates that it is not an effective drinking-water disinfectant. It should be noted that two silver
566 containing products have failed the WHO evaluation scheme for household water treatment products
567 (WHO, 2018), one was a colloidal silver dispersion added to water and the other a silver-treated ceramic
568 filter. WHO does not support the use of silver as a drinking-water disinfectant. Its efficacy is uncertain,
569 and any effect requires higher concentrations and lengthy contact periods (WHO, 2018). The use of
570 silver in combination with copper as a measure to reduce colonization and growth of *Legionella* spp. in
571 water distribution systems in buildings has proven effective in many cases. The positive effects are
572 based on long contact times in building water distribution systems (WHO, 2018)
573

574 **9 CONCLUSION**

575 9.1 Derivation of the health-based value and/or final guideline value

576 Silver is rarely found at notable concentrations in drinking-water except as a consequence of its use in
577 point of use water treatment devices or in the distribution systems of buildings when applied for
578 *Legionella* control in combination with copper ions. It is mostly found in the low $\mu\text{g/l}$ range in drinking-
579 water. Recognizing that silver has been used by humans for thousands of years, the data on toxic effects
580 of silver in humans other than as the cause for argyria are very limited. Data obtained from studies in
581 animals, including those for AgNP at very high concentrations hint at some toxic effects that are of
582 unclear relevance to the silver concentrations usually found in drinking-water.

583
584 The efficacy data on silver as a disinfectant are not comprehensive and there are concerns for all
585 applications other than its combination with copper for preventive *Legionella* management in building
586 water distribution systems where very long, contact times are allowed

587
588 The toxicological database on silver is not adequate to support derivation of a formal Guideline value.
589 Nevertheless, it is recognized that a “bounding value” may be useful. Striking diffuse, blue-gray skin
590 discoloration was reported in a woman who ingested 1 L or about 34 mg colloidal silver per day for
591 approximately 16 months (0.6 mg/kg bw per day assuming 60 kg bw; Kim et al., 2009). This may be
592 the lowest chronic LOAEL in humans. An uncertainty factor of 100 (10 each for intraspecies variability
593 and for limited data including use of a LOAEL) applied to the LOAEL of 0.6 mg/kg bw per day with
594 an allocation factor of 80 % and intake of 2 litres of drinking-water daily and 60 kg body weight, results
595 in a drinking-water concentration of approximately 0.1 mg/L. This concentration can be considered the
596 provisional reference value for silver in drinking-water (i.e. maximum allowable concentration),
597 particularly where silver/copper is used in the control of *Legionella* in the distribution systems of
598 buildings or where silver is used in point of use water treatment devices. 80% was chosen as an
599 allocation factor for such situations since these circumstances would result in drinking-water
600 contributing to the major source of silver exposure. In respect of the use of silver/copper in *Legionella*
601 management it is normal practice to only apply this to the hot water system but it is recognised that
602 occasionally there are circumstances where this is not possible and it is also applied to both the hot and
603 the cold water system.

604
605 This value is underpinned by the prior assessment that 10 g of ingested silver can be considered a human
606 NOAEL (WHO, 1993, 1984a,b; EPA 1992). Assuming 2 litres of drinking-water intake per day, 0.1
607 mg/L is a concentration in drinking-water that would give a total dose over 70 years of half this NOAEL.
608 However, as noted, there remains considerable uncertainties regarding the toxicity of silver (ions and
609 NPs) and this makes the data inappropriate for deriving a formal guideline value. Further, a formal
610 guideline value is considered unnecessary since the contribution of drinking-water to this NOAEL will
611 normally be negligible and since WHO does not recommend the use of silver for the disinfection of
612 drinking-water.

613

614 10 REFERENCES

615

616 AG (2016). Australian Drinking Water Guidelines 2011 Version 3.3 Updated November 2016, Australian
617 Government, National Health and Medical Research Council, National Resource Management Ministerial
618 Council, Canberra

619 Aktepe N, Kocyigit A, Yukselten Y, Taskin A, Keskin C, Celik H (2015) Increased DNA damage and oxidative
620 stress among silver jewelry workers. *Biological Trace Element Research*, 185-191.

621 ANSES (2011). Second French Total Diet Study (TDS 2). Report 1 – Inorganic contaminants, minerals, persistent
622 organic pollutants, mycotoxins and phytoestrogens. ANSES Opinion. Maisons-Alfort: Agence nationale de
623 sécurité sanitaire de l'alimentation, de l'environnement et du travail (French agency for food, environmental and
624 occupational health & safety) (<https://www.anses.fr/sites/default/files/documents/PASER2006sa0361Ra1EN.pdf>,
625 accessed 5 January 2015).

SILVER IN DRINKING-WATER

DRAFT Background document for the WHO GDWQ, December 2020

- 626 Arora S, Jain J, Rajwade JM and Paknikar KM (2008) Cellular responses induced by silver nanoparticles: In vitro
627 studies. *Tox Let* 179: 93-100
- 628 Asakura, K., H. Satoh, M. Chiba, M. Okamoto, K. Serizawa, M. Nakano, and K. Omae. 2009. Genotoxicity studies
629 of heavy metals: lead, bismuth, indium, silver and antimony. *J Occup Health*. 51(6):498-512.
- 630 ATSDR (1990). Toxicological profile for silver. Atlanta (GA): Agency for Toxic Substances and Disease
631 Registry.
- 632 Barillo DJ, Marx, DE (2014). Silver in medicine: A brief history BC 335 to present. *Burns* 40S, S3-S8
- 633 Boudreau, M.D., Imam, M.S., Paredes, A.M., Bryant, M.S., Cunningham, C.K., Felton, R.P., Jones, M.Y., Davis,
634 K.J. and Olson, G.R., 2016. Differential effects of silver nanoparticles and silver ions on tissue accumulation,
635 distribution, and toxicity in the Sprague Dawley rat following daily oral gavage administration for 13 weeks.
636 *Toxicological Sciences*, 150(1), pp.131-160.
- 637 Brock TD, Madigan MT, Martinko JM, Parker J (1994). Host–parasite relationships. In: *Biology of*
638 *microorganisms*, seventh edition. Engelwood Cliffs (NJ): Prentice-Hall International; 416–7.
- 639 Butkus MA, Labare MP, Starke JA, Moon K, Talbot M (2004). Use of aqueous silver to enhance inactivation of
640 coliphage MS-2 by UV disinfection. *Appl Environ Microbiol*. 70(5):2848–53.
- 641 Carlson C, Hussain SM, Schrand AM, Braydich-Stolle LK, Hess KL, Jones RL et al. (2008). Unique cellular
642 interaction of silver nanoparticles: size-dependent generation of reactive oxygen species. *J Phys Chem B*.
643 112(43):13608–19.
- 644 Castellini C, Ruggeri S, Mattioli S, Bernardini G, Macchioni L, Moretti E et al. (2014). Long-term effects of silver
645 nanoparticles on reproductive activity of rabbit buck. *Syst Biol Reprod Med*. 60(3):143–50.
- 646 Casto BC, Meyers J, DiPaolo JA (1979). Enhancement of viral transformation for evaluation of the carcinogenic
647 or mutagenic potential of inorganic metal salts. *Cancer Res*. 39(1):193–8.
- 648 De Gusseme B, Sintubin L, Baert L, Thibo E, Hennebel T, Vermeulen G et al. (2010). Biogenic silver for
649 disinfection of water contaminated with viruses. *Appl Environ Microbiol*. 76(4):1082–7.
- 650 Demerec M, Bertani G, Flint J (1951). A survey of chemicals for mutagenic action on *E. coli*. *Am Nat*.
651 85(821):119–36.
- 652 Denizeau F, Marion M (1989). Genotoxic effects of heavy metals in rat hepatocytes. *Cell Biol Toxicol*. 5(1):15–
653 25.
- 654 Dequidt J, Vasseur P, Gromez-Potentier J (1974). [Experimental toxicological study of some silver derivatives.]
655 *Bull Soc Pharm Lille*. 1:23–35 (in French).
- 656 Dobrzynska MM, Gajowik A, Radzikowska J, Lankoff A, Dusinska M, Kruszewski M (2014). Genotoxicity of
657 silver and titanium dioxide nanoparticles in bone marrow cells of rats in vivo. *Toxicology*. 315:86–91.
- 658 Drake PL, Hazelwood KJ (2005). Exposure-related health effects of silver and silver compounds: a review. *Ann*
659 *Occup Hyg*. 49(7):575–85.
- 660 Drasch G, Gath HJ, Heissler E, Schupp I, Roider G (1995). Silver concentrations in human tissues. Their
661 dependence on dental amalgam and other factors. *J Trace Elem Med Biol*. 9:82–7.
- 662 Durán N, Silveira CP, Durán M, Martínez DS (2015). Silver nanoparticle protein corona and toxicity: a
663 mini-review. *J Nanobiotechnol* 13:55
- 664 East BW, Boddy K, Williams ED, Macintyre D, McLay ALC (1980). Silver retention, total body silver and tissue
665 silver concentrations in argyria associated with exposure to an anti-smoking remedy containing silver acetate.
666 *Clin Exp Dermatol*. 5(3):305–11.
- 667 Eliopoulos P, Mourelatos D (1998). Lack of genotoxicity of silver iodide in the SCE assay in vitro, in vivo, and
668 in the Ames/microsome test. *Teratogen Carcinogen Mutagen*. 18(6):303–8.
- 669 Ema M, Okuda H, Gamo M, Honda K (2017). A review of reproductive and developmental toxicity of silver
670 nanoparticles in laboratory animals. *Reprod Toxicol*. 67:149-164.
- 671 Fewtrell L, Majuru B, Hunter PR (2017). A re-assessment of the safety of silver in household water treatment:
672 rapid systematic review of mammalian in vivo genotoxicity studies. *Environ Health*. 16(1):66.

SILVER IN DRINKING-WATER

DRAFT Background document for the WHO GDWQ, December 2020

- 673 Fowler B, Nordberg G (1986). Silver. In: Friberg L, Nordberg GF, Vouk VB, editors. Handbook on the toxicology
674 of metals. Amsterdam: Elsevier; 521–31.
- 675 Furchner JE, Richmond CR, Drake GA (1968). Comparative metabolism of radionuclides in mammals – IV.
676 Retention of silver-110m in the mouse, rat, monkey, and dog. *Health Phys.* 15(6):505–14.
- 677 Furst A, Schlauder MC (1978). Inactivity of two noble metals as carcinogens. *J Environ Pathol Toxicol.* 1(1):51–
678 7.
- 679 Garbos S, Swiecicka D (2013). Human exposure to silver released from silver-modified activated carbon applied
680 in the new type of jug filter systems. *Rocz Panstw Zakl Hig.* 64(1):31–6.
- 681 Gaul L, Staud A (1935). Clinical spectroscopy. Seventy cases of generalized argyrosis following organic and
682 colloidal silver medication. *J Am Med Assoc.* 104:1387–90.
- 683 Gibson R, Scythes C (1984). Chromium, selenium, and other trace element intakes of a selected sample of
684 Canadian premenopausal women. *Biol Trace Elem Res.* 6(2):105–16.
- 685 Goldberg AA, Shapero M, Wilder E (1950). Antibacterial colloidal electrolytes: the potentiation of the activities
686 of mercuric-, phenylmercuric- and silver ions by a colloidal sulphonic anion. *J Pharm Pharmacol.* 2(1):20–6.
- 687 Haase H, Fahmi A, Mahltig B (2014). Impact of silver nanoparticles and silver ions on innate immune cells. *J*
688 *Biomed Nanotechnol.* 10(6):1146–56.
- 689 Hammond C (1994). The elements. In: Lide D, editor. *CRC handbook of chemistry and physics.* Boca Raton (FL):
690 CRC Press; 75.
- 691 Hadrup N, Lam HR (2014). Oral toxicity of silver ions, silver nanoparticles and colloidal silver – A review.
692 *Regulatory Toxicology and Pharmacology* 68, 1–7.
- 693 Heidarpour F, Wan Ab Karim Ghani WA, Fakhru'l-Razi A, Sobri S, Heydarpour V, Zargar M et al. (2011).
694 Complete removal of pathogenic bacteria from drinking water using nano silver-coated cylindrical polypropylene
695 filters. *Clean Technol Environ Policy.* 13(3):499–507.
- 696 Hetzer B, Burcza A, Gräf V, Walz E, Greiner R (2017) Online-coupling of AF4 and single particle-ICP-MS as an
697 analytical approach for the selective detection of nanosilver release from model food packaging films into food
698 simulants. *Food Control* 80, 113-124.
- 699 Hill W, Pillsbury D (1939). *Argyria, the pharmacology of silver.* Baltimore (MD): Williams and Wilkins.
- 700 Hirasawa F, Sato M, Takizawa Y (1994). Organ distribution of silver and the effect of silver on copper status in
701 rats. *Toxicol Lett* 70:193–201
- 702 Holleman A, Wiberg E (2017). [Textbook of inorganic chemistry.], 103rd edition Berlin: Walter de Gruyter (in
703 German).
- 704 Hultman P, Lindh U, Horsted-Bindslev P (1998). Activation of the immune system and systemic immune-
705 complex deposits in brown Norway rats with dental amalgam restorations. *J Dent Res.* 77(6):1415–25.
- 706 Huynh KA, Siska E, Heithmar E, Tadjiki S, Pergantis, SA (2016). Detection and Quantification of Silver
707 Nanoparticles at Environmentally Relevant Concentrations Using Asymmetric Flow Field-Flow Fractionation
708 Online with Single Particle Inductively Coupled Plasma Mass Spectrometry. *Anal Chem.* 88 (9) 4909-4916
- 709 IARC (2014). Agents classified by the IARC Monographs, Volumes 1–111. Lyon: International Agency for
710 Research on Cancer (<http://monographs.iarc.fr/ENG/Classification/ClassificationsAlphaOrder.pdf>, accessed 5
711 January 2015).
- 712 Jiang X, Foldbjerg R, Miclaus T, Wang L, Singh R, Hayashi Y et al. (2013). Multi-platform genotoxicity analysis
713 of silver nanoparticles in the model cell line CHO-K1. *Toxicol Lett.* 222(1):55–63.
- 714 Kent NL, McCance RA (1941). The absorption and excretion of “minor” elements by man: silver, gold, lithium,
715 boron and vanadium. *Biochem J.* 35(7):837–44.
- 716 Kim YS, Kim JS, Cho HS et al. (2008). Twenty-eight-day oral toxicity, genotoxicity, and gender-related tissue
717 distribution of silver nanoparticles in Sprague-Dawley rats. *Inhal Toxicol* 20(6):575-83.
- 718 Kim JS, Sung JH, Ji JH, Song KS, Lee JH, Kang CS et al. (2011). In vivo genotoxicity of silver nanoparticles
719 after 90-day silver nanoparticle inhalation exposure. *Saf Health Work.* 2(1):34–8.

SILVER IN DRINKING-WATER

DRAFT Background document for the WHO GDWQ, December 2020

- 720 Kim Y, Suh HS, Cha HJ, Kim SH, Jeong KS, Kim DH (2009). A case of generalized argyria after ingestion of
721 colloidal silver solution. *Am J Ind Med.* 52(3):246–50.
- 722 Kim YS, Song MY, Park JD, Song KS, Ryu HR, Chung YH et al. (2010). Subchronic oral toxicity of silver
723 nanoparticles. *Particle and Fibre Toxicology* 7:20.
- 724 Kittler S, Greulich C, Diendorf J, Köller M, Epple M (2011): Toxicity of Silver Nanoparticles Increases during
725 Storage Because of Slow Dissolution under Release of Silver Ions, *Chem. Mater.* 2010, 22, 4548–4554
- 726 Li Y, Chen DH, Yan J, Chen Y, Mittelstaedt RA, Zhang Y et al. (2012). Genotoxicity of silver nanoparticles
727 evaluated using the Ames test and in vitro micronucleus assay. *Mutat Res.* 745(1–2):4–10.
- 728 Li Y, Bhalli JA, Ding W, Yan J, Pearce MG, Sadiq R et al. (2014). Cytotoxicity and genotoxicity assessment of
729 silver nanoparticles in mouse. *Nanotoxicology.* 8(Suppl 1):36–45.
- 730 Loeschner K, Hadrup N, Qvortrup K, Larsen A, Gao X., Vogel U et al. (2011). Distribution of silver in rats
731 following 28 days of repeated oral exposure to silver nanoparticles or silver acetate. *Particle and Fibre Toxicology*
732 8:18
- 733 Lyon TDB, Patriarca M, Howatson AG, Fleming PJ, Blair PS, Fell GS (2002). Age dependence of potentially
734 toxic elements (Sb, Cd, Pb, Ag) in human liver tissue from paediatric subjects. *J Environ Monit.* 4(6):1034–9.
- 735 Maneewattanapinyo P, Banlunara W, Thammacharoen C, Ekgasit S, Kaewamatawong T (2011). An Evaluation
736 of Acute Toxicity of Colloidal Silver Nanoparticles, *J. Vet. Med. Sci.* 73(11): 1417–1423
- 737 Marin, S, Vlasceanu GM, Tiplea RE, Bucur IR, Lemnaru M, Marin MM, Grumezescu AM (2015). Applications
738 and Toxicity of Silver Nanoparticles: A Recent Review *Current Topics in Medicinal Chemistry* 15: 1596-1604
- 739 Matuk Y, Ghosh M, McCulloch C (1981). Distribution of silver in the eyes and plasma proteins of the albino rat.
740 *Can J Ophthalmol.* 16:145–50.
- 741 Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE
742 (2014). In vivo human time-exposure study of orally dosed commercial silver nanoparticles. *Nanomedicine*, 10(1)
743 1-9.
- 744 Murthy GK, Rhea U (1968). Cadmium and silver content of market milk. *J Dairy Sci.* 51(4):610–3.
- 745 NAS (1982). *Drinking water and health.* Washington (DC): National Academy of Sciences.
- 746 Nel A, Xia T, Li N. (2006). Toxic Potential of Materials at the Nanolevel. *Science* 311, 622
- 747 Neri LC, Hewitt D, Schreiber GB, Arderson TW, Mandel JS, Zdrojewsky A (1974). Health Aspects of Hard and
748 Soft Waters, *Journal of American Water Works Association.* 67:403
- 749 Nishioka H (1975). Mutagenic activities of metal compounds in bacteria. *Mutat Res.* 31(3):185–9.
- 750 Nordberg G, Gerhardsson L (1988). Silver. In: Seiler HG, Sigel H, Sigel A, editors. *Handbook on the toxicity of*
751 *inorganic compounds.* New York (NY): Marcel Dekker; 619–24.
- 752 NTP (2016). 14th report on carcinogens. Research Triangle Park (NC): United States Department of Health and
753 Human Services, Public Health Service, National Toxicology Program
754 (<https://ntp.niehs.nih.gov/pubhealth/roc/index-1.html#toc1>, accessed 20 July 2018).
- 755 Olcott CT (1947). Experimental argyrosis: III. Pigmentation of the eyes of rats following ingestion of silver during
756 long periods of time. *Am J Pathol.* 23(5):783–91.
- 757 Olcott CT (1948). Experimental argyrosis; morphologic changes in the experimental animal. *Am J Pathol.*
758 24(4):813–33.
- 759 Olcott CT (1950). Experimental argyrosis; hypertrophy of the left ventricle of the heart in rats ingesting silver
760 salts. *AMA Arch Pathol.* 49(2):138–49.
- 761 Oppenheimer BS, Oppenheimer ET, Danishefsky I et al. (1956). Carcinogenic effect of metals in rodents. *Cancer*
762 *Res.* 16:439–41. Park K, Park E-J, Chun IK, Choi K, Lee SH, Yoon J, Lee BC. (2011) Bioavailability and
763 Toxicokinetics of Citrate-coated Silver Nanoparticles in Rats *Arch Pharm Res* 34, 153-158
- 764 Park EJ, Bae E, Yi J, Kim Y, Choi K, Lee SH et al. (2010). Repeated-dose toxicity and inflammatory responses
765 in mice by oral administration of silver nanoparticles, *Env Tox Pharm* 30: 162-168

SILVER IN DRINKING-WATER

DRAFT Background document for the WHO GDWQ, December 2020

- 766 Patolla AK, Hackett D, Tchounwou PB (2015). Genotoxicity study of silver nanoparticles in bone marrow cells
767 of Sprague-Dawley rats. *Food Chem Toxicol.* 85: 52-60.
- 768 Pelkonen KH, Heinonen-Tanski H, Hanninen OO (2003). Accumulation of silver from drinking water into
769 cerebellum and musculus soleus in mice. *Toxicology.* 186(1–2):151–7.
- 770 Price CJ and George JD. (2002) Final study report on the developmental toxicity evaluation for silver acetate
771 (CAS No. 563-63-3) administered by gavage to Sprague-Dawley (CDN) rats on gestational days 6 through 19.
772 NTIS Technical Report (NTIS/PB2002-109208).
- 773 Reedy CR, Bridget RS, Walden S, Strassberg G (2011). Final Contract Report prepared for the Texas Water
774 Development Board. Bureau of Economic Geology, The University of Texas at Austin, Contract Number
775 1004831125
- 776 Rungby J (1990). An experimental study on silver in the nervous system and on aspects of its general cellular
777 toxicity. *Dan Med Bull.* 37:442–9.
- 778 Rungby J, Danscher G (1984). Hypoactivity in silver exposed mice. *Acta Pharmacol Toxicol.* 55(5):398–401.
- 779 Salih HM, El Badawy, AM, Tolaymat TM, Patterson CL (2019). Removal of Stabilized Silver Nanoparticles from
780 Surface Water by Conventional Treatment Processes. *Adv. Nanopart.*, 8, 21-35
- 781 Sardari, R.R.R., Zarchi, S.R., Talebi, A., Nasri, S., Imani, S., Khoradmehr, A. and Sheshde, S.A.R., 2012.
782 Toxicological effects of silver nanoparticles in rats. *African Journal of Microbiology Research*, 6(27), pp.5587-
783 5593.
- 784 Schaumann GE, Philippe A, Bundschuh M, Metreveli G, Klitzke S, Rakcheev D. (2014) Understanding the fate
785 and biological effects of Ag- and TiO₂-nanoparticles in the environment: The quest for advanced analytics and
786 interdisciplinary concepts. *Sci Total Environ.* <http://dx.doi.org/10.1016/j.scitotenv.2014.10.035>
- 787 Schmahl D, Steinhoff D (1960). [Experimental carcinogenesis in rats with colloidal silver and gold solutions]. *Z*
788 *Krebsforsch.* 63:586–91(in German).
- 789 Shresta S, Wang B, Dutta P (2020): Nanoparticle processing: Understanding and controlling aggregation. *Adv*
790 *Colloid Interface Sci.* 279, 102162
- 791 Skare I, Engqvist A. (1994): Human Exposure to Mercury and Silver Released from Dental Amalgam
792 Restorations. *Arch Env Health*, 49(5): 384-394
- 793 Sleiman HK, Romano RM, Oliveira CA, Romano MAJ (2013). Effects of prepubertal exposure to silver
794 nanoparticles on reproductive parameters in adult male Wistar rats. *Toxicol Environ Health A.* 76(17):1023–32.
- 795 Sterling JP (2014). Silver-resistance, allergy, and blue skin: truth or urban legend? *Burns.* 40(Suppl 1):S19–23.
- 796 Stoiber T, Croteau MN, Römer I, Tejamaya M, Lead JR, Luoma SN. (2015) Influence of hardness on the
797 bioavailability of silver to a freshwater snail after waterborne exposure to silver nitrate and silver nanoparticles.
798 *Feb 13:1-10.* [Epub ahead of print]
- 799 Syafiuddin A, Fulazzaky MA, Salmiati S, Kueh ABH, Fulazzaky M, Salim MR (2020): Silver nanoparticles
800 adsorption by the synthetic and natural adsorbent materials: an exclusive review, *Nanotechnology for*
801 *Environmental Engineering*, 5:1
- 802 Takenaka S, Karg E, Roth C, Schulz H, Ziesenis A, Heinzmann U et al. (2001). Pulmonary and systemic
803 distribution of inhaled ultrafine silver particles in rats. *Environ Health Perspect.* 109(Suppl 4):547–51.
- 804 Thakur M, Gupta H, Singh D, Mohanty IR, Maheswari U, Vanage G and Joshi DS. (2014). Histopathological and
805 ultra structural effects of nanoparticles on rat testis following 90 days (Chronic study) of repeated oral
806 administration. *Journal of Nanobiotechnology*, 12:42
- 807 USEPA (1977). Manual of treatment techniques for meeting the interim primary drinking water regulations.
808 Report No. EPA-600/8-77-005: pp. 32-33 Cincinnati, OH, United States Environmental Protection Agency.
- 809 USEPA (1980). Ambient water quality criteria for silver. Washington (DC): United States Environmental
810 Protection Agency.
- 811 USEPA (1992). Silver drinking water health advisory. Washing (DC): United States Environmental Protection
812 Agency.

SILVER IN DRINKING-WATER

DRAFT Background document for the WHO GDWQ, December 2020

- 813 USEPA (2007). Method 200.8 – Determination of trace elements in waters and wastes by inductively coupled
814 plasma – mass spectrometry. Cincinnati (OH): United States Environmental Protection Agency, Office of
815 Research and Development, Environmental Monitoring Systems Laboratory.
- 816 USEPA (2012). 2012 Edition of the Drinking Water Standards and Health Advisories, United States
817 Environmental Protection Agency, Washington (DC), Document nr. EPA 822-S-12-001
- 818 USEPA (2014). Silver (CASRN 7440-22-4). Washington (DC): United States Environmental Protection Agency,
819 Integrated Risk Information System (<http://www.epa.gov/iris/subst/0099.htm>, accessed 3 December 2014).
- 820 USEPA (2017): Secondary Drinking Water Standards: Guidance for Nuisance Chemicals, web access:
821 [https://www.epa.gov/dwstandardsregulations/secondary-drinking-water-standards-guidance-nuisance-](https://www.epa.gov/dwstandardsregulations/secondary-drinking-water-standards-guidance-nuisance-chemicals#table)
822 [chemicals#table](https://www.epa.gov/dwstandardsregulations/secondary-drinking-water-standards-guidance-nuisance-chemicals#table), accessed June 2018
- 823 van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, , et al. (2012). Distribution,
824 elimination, and toxicity of silver nanoparticles and silver ions in rats after 28-day oral exposure. *ACS Nano*
825 *6*(8):7427-42.
- 826 Wagner PA, Hoekstra WG, Ganther HE (1975). Alleviation of silver toxicity by selenite in the rat in relation to
827 tissue glutathione peroxidase. *Exp Biol Med.* 148(4):1106–10
- 828 Warrington PD (1996). Ambient water quality criteria for silver. Victoria (BC): British Columbia Ministry of
829 Environment, Lands and Parks, Water Quality Branch, Environmental Protection Department
830 ([http://www2.gov.bc.ca/assets/gov/environment/air-land-water/water/waterquality/wqgs-wqos/approved-](http://www2.gov.bc.ca/assets/gov/environment/air-land-water/water/waterquality/wqgs-wqos/approved-wqgs/silver-tech.pdf)
831 [wqgs/silver-tech.pdf](http://www2.gov.bc.ca/assets/gov/environment/air-land-water/water/waterquality/wqgs-wqos/approved-wqgs/silver-tech.pdf)).
- 832 Walker, F. 1971. Experimental argyria: A model for basement membrane studies. *Br. J. Exp. Path.* 52: 589-593.
- 833 Westhofen M, Schäfer H (1986). Generalized argyrosis in man: neurotological, ultrastructural and X-ray
834 microanalytical findings. *Arch Otorhinolaryngol.* 243(4):260–4.
- 835 Whitlow SI, Rice DL (1985). Silver complexation in river waters of central New York. *Water Res.* 19(5):619–26.
- 836 WHO (1984a). Guidelines for drinking-water quality: Volume 1: recommendations. World Health Organization,
837 Geneva, Switzerland.
- 838 WHO (1984b). Guidelines for drinking-water quality: Volume 2: Health Criteria and other supporting
839 information. World Health Organization, Geneva, Switzerland.
- 840 WHO (1993). Guidelines for drinking-water quality: second edition. Volume 1: recommendations. World Health
841 Organization, Geneva, Switzerland.
- 842 WHO (2018). Silver as a drinking-water disinfectant, World Health Organization, Geneva, Switzerland.